Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MC2S
|
|||
| Former ID |
DIB006647
|
|||
| Drug Name |
NIC-002
|
|||
| Synonyms |
NicQb; Nicotine-Qbeta; CYT-002-NicQb; Nicotine vaccine, Cytos/Novartis; Immunodrug (nicotine addiction), Cytos/Novartis
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Nicotine dependence [ICD-11: 6C4A.2; ICD-10: F17.2; ICD-9: 305.1] | Phase 2 | [1] | |
| Company |
Cytos Biotechnology AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nicotinic acetylcholine receptor (nAChR) | Target Info | . | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Highly sodium permeable acetylcholine nicotinic receptors | |||
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00369616) Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers. U.S. National Institutes of Health. | |||
| REF 2 | Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.